AstraZeneca
AstraZeneca leukaemia treatment recommended for NHS use
March 18, 2021AstraZeneca, NHS
AstraZeneca has announced today that its oral targeted cancer therapy, Calquence (acalabrutinib), has been recommended by NICE for routine use …
AstraZeneca vaccine suspended in 11 European countries
March 16, 2021Manufacturing and Production AstraZeneca
Blood clot fears have caused 11 European countries to suspend the use of the Oxford-AstraZeneca vaccine. France, Germany, Italy, and …
Netherlands suspends AstraZeneca vaccine despite safety assurances
March 15, 2021Medical Communications, Sales and Marketing AstraZeneca, COVID-19, EMA, EU, WHO
The Netherlands has become the latest country to suspend the use of the Oxford-AstraZeneca vaccine amid concerns it may cause …
AstraZeneca wins US court ruling on Symbicort patent claims
March 3, 2021Research and Development AstraZeneca, Symbicort, law
A US district court has ruled in favour of AstraZeneca in litigation against Mylan Pharmaceuticals and Kindeva Drug Delivery, AstraZeneca …
Single Pfizer or AstraZeneca vaccine dose drastically reduces COVID-19 hospitalisations in over-80s
March 2, 2021Manufacturing and Production AstraZeneca, COVID-19, COVID-19 vaccine, Pfizer, Vaccine
A single dose of the Oxford-AstraZeneca or the Pfizer-BioNTech vaccine reduces UK hospitalisations in over-80s by 80%, a Public Health …
AstraZeneca to withdraw Imfinzi US indication for bladder cancer
February 22, 2021Sales and Marketing AstraZeneca, Imfinzi
AstraZeneca will voluntarily withdraw the Imfinzi (durvalumab) indication in the US for previously treated adult patients with locally advanced or …
AstraZeneca and MSD’s Lynparza crosses superiority boundary for invasive disease-free survival
February 17, 2021Research and Development AstraZeneca, Cancer, MSD
The OlympiA Phase III trial for AstraZeneca and MSD’s cancer drug Lynparza will move to early primary analysis and reporting, …
WHO approves two versions of AstraZeneca’s COVID-19 vaccine
February 16, 2021Manufacturing and Production AstraZeneca, COVID-19, WHO
The WHO has greenlighted two versions of the Oxford-AstraZeneca COVID-19 vaccine for emergency use, granting them authorisation to be rolled …
Daiichi Sankyo and AstraZeneca’s breast cancer drug Enhertu approved in UK
February 16, 2021Manufacturing and Production AstraZeneca, Cancer, Daiichi Sankyo
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has been granted conditional authorisation in the UK as a monotherapy for the …
AstraZeneca’s COVID-19 vaccine to be trialled in children
February 15, 2021Sales and Marketing AstraZeneca, COVID-19
The Oxford-AstraZeneca COVID-19 vaccine is to be tested on children in the UK in a new trial commencing this month. …
AstraZeneca COVID-19 vaccine still restricted, despite WHO assurances
February 12, 2021Medical Communications AstraZeneca, COVID-19
Several European countries have continued to impose age restrictions on their rollouts of the Oxford University-AstraZeneca vaccine, despite WHO’s repeated …
WHO panel recommends AstraZeneca COVID-19 vaccine for over-65s
February 11, 2021AstraZeneca, COVID-19, WHO
Scientists advising the WHO have recommended the use of the Oxford-AstraZeneca COVID-19 vaccine in all adults, including those aged over …
South Korea approves AstraZeneca COVID-19 vaccine for use
February 10, 2021Research and Development AstraZeneca, COVID-19
South Korea is to grant first approval for the Oxford University-AstraZeneca vaccine later today, with the rollout expected to start …
South Africa halts rollout of AstraZeneca’s COVID-19 vaccine amid efficacy concerns
February 8, 2021Sales and Marketing AstraZeneca, COVID-19
AstraZeneca is racing to adapt its COVID-19 vaccine as new data suggests it offers little protection against the more dominant …
New Oxford University-AstraZeneca vaccine against COVID-19 mutations could be available by October
February 5, 2021Medical Communications AstraZeneca, COVID-19
Oxford University and AstraZeneca could release a new vaccine by October in order to counter the new mutations of COVID-19 …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
